The immunotherapy combination of relatlimab and nivolumab delivered durable survival rates in patients with advanced, unresectable melanoma, with 80% of patients remaining event-free. Read more about this research ↓.

In an exclusive interview, Amir Jazaeri, MD, @MDAndersonNews, discusses innovative methods for detecting MRD in ovarian cancer, enhancing prognosis and paving the way for targeted therapies. Read the full story:

What do you want to know?.

A new phase 2 study shows Alpha1H is highly effective & safe for non–muscle-invasive bladder cancer (NMIBC), shrinking tumors by 59% with no serious adverse effects. Find out how this novel therapy could change NMIBC treatment.

Emerging treatments for low-grade serous ovarian cancer and platinum-resistant disease offer new hope, with promising data from recent clinical trials. Read about these exciting clinical developments here:

The FDA approved Agilent's MMR IHC Panel, enhancing personalized colorectal cancer treatment by identifying patients for targeted immunotherapy options. Read the full story:

Pembrolizumab showed strong antitumor activity in patients with unresectable desmoplastic melanoma. Learn more about this research here:

WATCH: Binod Dhakal, MD, explores innovative bridging therapies for multiple myeloma, enhancing patient outcomes before CAR T-cell treatment while addressing significant challenges. Check out the full interview:

In an exclusive interview, David Andorsky, MD, explores the evolving treatment landscape of chronic myeloid leukemia with asciminib, a promising TKI showing high efficacy and safety.

WATCH: Jason Luke, MD, discusses IMA203, which showed an excellent safety profile and promising efficacy in solid tumors, leading to a new registration-directed clinical trial.

A significant number of patients with ovarian cancer miss preventive salpingectomy opportunities during unrelated surgeries. Learn more on this research here:

A new combination therapy shows promising results for advanced non-small cell lung cancer, offering hope for patients with limited treatment options. Read the full story →

New research reveals that GLP-1 receptor agonists significantly lower mortality risk in older cancer patients with type 2 diabetes compared to other treatments. Read more →

⏰ Final days to submit your Oncology Icons nomination — deadline is August 22! We need your help in honoring an oncologist making significant impact in their community. 🏆 Nominate now:

A novel "off-the-shelf" allogeneic CAR T-cell therapy demonstrated anti-tumor activity against #ovariancancer tumor cells from both newly diagnosed and relapsed/refractory patients. #gyncsm.

A new study reveals personalized treatment strategies for HER2-negative breast cancer, optimizing antibody-drug conjugate sequencing based on tumor characteristics. Read more →

Mabwell's 7MW4911 has received FDA IND clearance, paving the way for clinical trials targeting advanced GI cancers with promising preclinical results. Read the full story:

A groundbreaking study reveals ctDNA testing outperforms traditional imaging in predicting outcomes for patients with large B-cell lymphoma, enhancing treatment strategies. Read more →

Early results from the TUSCANY trial highlight promising remission rates and safety for a new triplet therapy in treating acute myeloid leukemia. Read the full story →

A systemic review of patient-reported outcome measures used in melanoma research and clinical practice reveals high heterogeneity and gaps in melanoma-specific validation data. Read more:

Cancer vaccine ELI-002 is being studied in patients with KRAS-mutated tumors and has shown a significant reduction in cancer recurrence in patients who had a strong immune response.